Sunday 18 October 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022. In the quarter to June 2026, EPS grew 88.5% and free cash flow grew 9.77%, each against the same quarter a year earlier.
3.36
0.23
−6.41%
Follow UNCY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(84.15%) | (141.14%) | (163.14%) | (101.07%) | |
| (61.64%) | (65.73%) | (86.51%) | (69.05%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(73.83%) | (88.25%) | (107.65%) | (66.89%) | |
Free Cash Flow per Share |
(1.65) | (1.97) | (1.20) | (1.03) | |
Free Cash Flow |
(29.88) | (31.34) | (28.67) | (27.85) | |
Capital Expenditures |
(0.05) | (0.02) | (0.02) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(37.27%) | (43.85%) | (31.07%) | (24.28%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(500.87) | (415.73) | (535.09) | — | |
Operating CF/Net income |
1.09 | 1.18 | 0.72 | 0.79 | |
Depreciation/Fixed assets |
7.40 | 8.67 | 13.75 | 15.61 | |
Capex/Depreciation |
(0.08) | (0.04) | (0.02) | (0.01) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.65) | (1.97) | (1.20) | (1.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates